Svetlana N. Bykovskaia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Svetlana N. Bykovskaia has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Daria D. Eliseeva
Russian Center of Neurology and Neurosciences
2 shared publications - Alexander Viktorovich Karaulov
Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
1 shared publication Anastasia V. Lokhonina
A Pirogov Russian National Research Medical University , Moscow , Russia
1 shared publicationDmitry D. Zhdanov
A Pirogov Russian National Research Medical University , Moscow , Russia
1 shared publicationElena Y. Lyssuck
A Pirogov Russian National Research Medical University , Moscow , Russia
1 shared publicationGelena V. Lifshitz
A Pirogov Russian National Research Medical University , Moscow , Russia
1 shared publication
Latest Publications
- 16 July 2016
- Published by Taylor & Francis in Autoimmunity
- Vol. 49 (6) , 388-396
Ex vivo expanded regulatory T cells CD4+CD25+FoxP3+CD127Low develop strong immunosuppressive activity in patients with remitting-relapsing multiple sclerosis
Multiple sclerosis (MS) is an autoimmune disease characterized by defect in regulatory function of CD4+CD25+ T cells. We demonstrated difference in proportion of regulatory T cells CD4+CD25+FoxP3+CD127low (Tregs) within the same patients’ relapse and remission. Proportion of peripheral Tregs (pTregs) dropped almost two times in the relapse compare to remission. Levels of pTregs in patients’ remission were lower than in healthy donors. Suppressive ability of pTregs was decreased in MS patients compared to healthy donors. Injections of expanded ex vivo autologous Tregs (eTregs) could be helpful in bringing up the level of Tregs in patients’ blood. We developed a simple method for ex vivo expansion of autologous Tregs within a short period of time. The final pool of cells consisted of 90-95% eTregs. When we started the culture with 10-20 × 106 CD4+ T cells, we yield 300-400 × 106 eTregs in a week. Expression of FoxP3 and Helios was calculated by two methods. Expanded ex vivo patients’ and donors’ Tregs were characterized by increased from three to five times expression of FoxP3, as well as almost doubled Helios expression. Peripheral Tregs in MS patients have decreased demethylation of FoxP3 gene promoter in comparison with donors. On the contrary, eTregs showed stable up-regulated demethylation without difference between MS patients and donors. MS patients’ and donors’ eTregs have much more suppressive ability than pTregs. Our data showed that eTregs can be applied as immunotherapy for MS patients and other autoimmune diseases if further investigated.
- 16 July 2016
- Published by Taylor & Francis in Autoimmunity
- Vol. 49 (6) , 388-396
Ex vivo expanded regulatory T cells CD4+CD25+FoxP3+CD127Low develop strong immunosuppressive activity in patients with remitting-relapsing multiple sclerosis
Multiple sclerosis (MS) is an autoimmune disease characterized by defect in regulatory function of CD4+CD25+ T cells. We demonstrated difference in proportion of regulatory T cells CD4+CD25+FoxP3+CD127low (Tregs) within the same patients’ relapse and remission. Proportion of peripheral Tregs (pTregs) dropped almost two times in the relapse compare to remission. Levels of pTregs in patients’ remission were lower than in healthy donors. Suppressive ability of pTregs was decreased in MS patients compared to healthy donors. Injections of expanded ex vivo autologous Tregs (eTregs) could be helpful in bringing up the level of Tregs in patients’ blood. We developed a simple method for ex vivo expansion of autologous Tregs within a short period of time. The final pool of cells consisted of 90-95% eTregs. When we started the culture with 10-20 × 106 CD4+ T cells, we yield 300-400 × 106 eTregs in a week. Expression of FoxP3 and Helios was calculated by two methods. Expanded ex vivo patients’ and donors’ Tregs were characterized by increased from three to five times expression of FoxP3, as well as almost doubled Helios expression. Peripheral Tregs in MS patients have decreased demethylation of FoxP3 gene promoter in comparison with donors. On the contrary, eTregs showed stable up-regulated demethylation without difference between MS patients and donors. MS patients’ and donors’ eTregs have much more suppressive ability than pTregs. Our data showed that eTregs can be applied as immunotherapy for MS patients and other autoimmune diseases if further investigated.
- Open Access
- 23 March 2012
- Published by Paediatrician Publishers LLC in Annals of the Russian academy of medical sciences
- Vol. 67 (3) , 68-74
THE ROLE OF REGULATORY T CELLS IN THE DEVELOPMENT OF AUTOIMMUNE PROCESS IN MULTIPLE SCLEROSIS
In the maintenance of immunological tolerance important role belongs to the recently discovered population of regulatory T-cells CD4 + CD25 + FoxP3 +. These cells have potential in suppressing pathologic immune responses observed at various autoimmune diseases including multiple sclerosis. We have shown a reduction in the number and functional activity of T-reg in peripheral blood of patients with multiple sclerosis in the acute stage, the increase in their number during remission, duration of the relationship of the autoimmune process and the degree of disability of patients with the contents of T-reg. The possibility of using the grown ex vivo T-reg for the correction of immunopathological process in multiple sclerosis.
- 23 March 2012
- Published by Paediatrician Publishers LLC in Annals of the Russian academy of medical sciences
- Vol. 67 (3) , 68-74
Open AccessTHE ROLE OF REGULATORY T CELLS IN THE DEVELOPMENT OF AUTOIMMUNE PROCESS IN MULTIPLE SCLEROSIS
In the maintenance of immunological tolerance important role belongs to the recently discovered population of regulatory T-cells CD4 + CD25 + FoxP3 +. These cells have potential in suppressing pathologic immune responses observed at various autoimmune diseases including multiple sclerosis. We have shown a reduction in the number and functional activity of T-reg in peripheral blood of patients with multiple sclerosis in the acute stage, the increase in their number during remission, duration of the relationship of the autoimmune process and the degree of disability of patients with the contents of T-reg. The possibility of using the grown ex vivo T-reg for the correction of immunopathological process in multiple sclerosis.